329 related articles for article (PubMed ID: 23863450)
1. Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.
Zhou Z; Wu X; Kresak A; Griswold M; Lu ZR
Biomaterials; 2013 Oct; 34(31):7683-93. PubMed ID: 23863450
[TBL] [Abstract][Full Text] [Related]
2. MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent.
Zhou Z; Qutaish M; Han Z; Schur RM; Liu Y; Wilson DL; Lu ZR
Nat Commun; 2015 Aug; 6():7984. PubMed ID: 26264658
[TBL] [Abstract][Full Text] [Related]
3. Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.
Wu X; Yu G; Lindner D; Brady-Kalnay SM; Zhang Q; Lu ZR
Am J Nucl Med Mol Imaging; 2014; 4(6):525-36. PubMed ID: 25250202
[TBL] [Abstract][Full Text] [Related]
4. An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma.
Pagoto A; Tripepi M; Stefania R; Lanzardo S; Livio Longo D; Garello F; Porpiglia F; Manfredi M; Aime S; Terreno E
Magn Reson Med; 2019 Mar; 81(3):1935-1946. PubMed ID: 30257047
[TBL] [Abstract][Full Text] [Related]
5. A Bioinspired Nanoprobe with Multilevel Responsive T
Li Y; Zhao X; Liu X; Cheng K; Han X; Zhang Y; Min H; Liu G; Xu J; Shi J; Qin H; Fan H; Ren L; Nie G
Adv Mater; 2020 Jan; 32(4):e1906799. PubMed ID: 31799765
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of a porphyrazine-Gd(III) MRI contrast agent and in vivo imaging of a breast cancer xenograft model.
Trivedi ER; Ma Z; Waters EA; Macrenaris KW; Subramanian R; Barrett AG; Meade TJ; Hoffman BM
Contrast Media Mol Imaging; 2014; 9(4):313-22. PubMed ID: 24706615
[TBL] [Abstract][Full Text] [Related]
7. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
8. Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging.
Tan M; Wu X; Jeong EK; Chen Q; Lu ZR
Biomacromolecules; 2010 Mar; 11(3):754-61. PubMed ID: 20131758
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.
Wu X; Burden-Gulley SM; Yu GP; Tan M; Lindner D; Brady-Kalnay SM; Lu ZR
Bioconjug Chem; 2012 Aug; 23(8):1548-56. PubMed ID: 22812444
[TBL] [Abstract][Full Text] [Related]
10. A targeted nanoglobular contrast agent from host-guest self-assembly for MR cancer molecular imaging.
Zhou Z; Han Z; Lu ZR
Biomaterials; 2016 Apr; 85():168-79. PubMed ID: 26874280
[TBL] [Abstract][Full Text] [Related]
11. MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.
Tan M; Burden-Gulley SM; Li W; Wu X; Lindner D; Brady-Kalnay SM; Gulani V; Lu ZR
Pharm Res; 2012 Apr; 29(4):953-60. PubMed ID: 22139536
[TBL] [Abstract][Full Text] [Related]
12. Design of (Gd-DO3A)n-polydiamidopropanoyl-peptide nucleic acid-D(Cys-Ser-Lys-Cys) magnetic resonance contrast agents.
Amirkhanov NV; Dimitrov I; Opitz AW; Zhang K; Lackey JP; Cardi CA; Lai S; Wagner NJ; Thakur ML; Wickstrom E
Biopolymers; 2008 Dec; 89(12):1061-76. PubMed ID: 18680101
[TBL] [Abstract][Full Text] [Related]
13. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1841-1855. PubMed ID: 38372766
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.
Xu D; Lu ST; Li YS; Baidya A; Mei H; He Y; Wu B
Drug Des Devel Ther; 2018; 12():3301-3309. PubMed ID: 30323562
[TBL] [Abstract][Full Text] [Related]
15. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.
Ye Z; Zhou Z; Ayat N; Wu X; Jin E; Shi X; Lu ZR
Contrast Media Mol Imaging; 2016; 11(1):32-40. PubMed ID: 26218648
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
17. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.
Ye F; Wu X; Jeong EK; Jia Z; Yang T; Parker D; Lu ZR
Bioconjug Chem; 2008 Dec; 19(12):2300-3. PubMed ID: 19053180
[TBL] [Abstract][Full Text] [Related]
18. Structural effect on degradability and in vivo contrast enhancement of polydisulfide Gd(III) complexes as biodegradable macromolecular MRI contrast agents.
Zong Y; Wang X; Jeong EK; Parker DL; Lu ZR
Magn Reson Imaging; 2009 May; 27(4):503-11. PubMed ID: 18814987
[TBL] [Abstract][Full Text] [Related]
19. An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.
Tan M; Wu X; Jeong EK; Chen Q; Parker DL; Lu ZR
Mol Pharm; 2010 Aug; 7(4):936-43. PubMed ID: 20481565
[TBL] [Abstract][Full Text] [Related]
20. In vivo labeling of B16 melanoma tumor xenograft with a thiol-reactive gadolinium based MRI contrast agent.
Menchise V; Digilio G; Gianolio E; Cittadino E; Catanzaro V; Carrera C; Aime S
Mol Pharm; 2011 Oct; 8(5):1750-6. PubMed ID: 21780833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
